Treatment of pediatric alopecia areata with anthralin: A retrospective study of 37 patients

Abstract

Background/ObjectivesData on treatment options in pediatric alopecia areata are limited. Topical anthralin has been demonstrated to be an effective treatment option in adults and has minimal systemic toxicity. Prior results on its efficacy in children with alopecia areata have been mixed.MethodsMedical records of 37 patients with alopecia areata who were started on topical anthralin before age 17 were reviewed for efficacy and safety data. Scalp regrowth was quantified by serial photography if available or by medical record documentation if photographs were unavailable. Mean duration of clinical follow‐up was 2.5 years.ResultsMost patients were started on anthralin while continued on prior therapies, including topical corticosteroids, minoxidil, and/or intralesional corticosteroids. Twelve patients (32%) experienced complete scalp regrowth, while 25 patients (68%) experienced at least 50% maximal scalp regrowth with using anthralin. Of the patients with at least 50% scalp regrowth, mean time to first clinically observed response was 3.4 months. Mean time to maximal response was 15 months. Four patients stopped anthralin due to skin irritation. Relapses affected 64% of those with at least 50% maximal scalp regrowth.ConclusionsTopical anthralin provides children with alopecia areata an additional option that offers potential for significant scalp regrowth with minimal systemic effects. Treatment course may need to be continued for at least 1 year in order to achieve maximal efficacy. The efficacy of anthralin may be limited by high rate of recurrence and local adverse effects.

Protective Role of Nutritional Plants Containing Flavonoids in Hair Follicle Disruption: A Review

“…HL is a symptom of a variety of several forms of alopecia, including AGA, AA, and telogen effluvium [110]. Recognized treatment involves the use of drugs that are effective only upon continued administration and are not free from side effects [110][111][112][113]. Some patients may find MXD use unhandy or expensive.…”

Repurposing of Ribavirin as an Adjunct Therapy against Invasive Candida Strains in an In Vitro Study

“…(iv) Reversible hemolytic anemia is the unique adverse effect observed with ribavirin treatment, in contrast to the cytotoxic effects that other molecules, such as thioguanine and avermectin B1, may have on human cells due to their nonselective activities (10,11). (v) Ribavirin can be administered orally (as a capsule or tablet), intravenously, or through inhalation (9), while only topical application is possible for some molecules, such as anthralin (12). That is why, in this study, a large panel of 100 Candida sp.…”

Italian Guidelines in diagnosis and treatment of alopecia areata

“…Evidence of its efficacy for AA is restricted to a small number of case series with inadequate controls. 60,61 Studies have suggested that anthralin may be effective high concentrations (0.5 or 1% cream) applied for short periods (20 to 30 minutes daily) on the alopecic scalp, in the so-called short-contact therapy. the time of contact is increased by 10 minutes every two weeks up to one hour or to the time required to produce a mild dermatitis.…”